Efgartigimod
argenx
[]
#ash22 broome: advance iv study: 131 patients with refractory itp were randomized 2:1 to efgartigamod vs placebo. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)